Page 22 - Pharma Companies

Revised, more industry-friendly PLI scheme for bulk drugs on the cards

Industry says move will mean lower spends and reduced dependence on China

Credit metrics of leading pharma companies to remain stable: ICRA

The global demand scenario for Indian pharmaceutical industry is largely expected to remain stable due to inelastic nature of prescription drugs, investment information agency ICRA has said.

Syngene: Investors with long term view should look at the stock on dips

While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US

According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US

Gilead nears deal to buy Immunomedics for more than $20 billion: Report

Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation

Gilead nears deal to buy Immunomedics for more than $20 bn: WSJ report

Gilead Sciences Inc is said to be nearing a deal to buy biopharmaceutical company Immunomedics Incfor more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments

BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis

It had posted a sales turnover of Rs 75.48 crore in the corresponding first quarter of previous fiscal year, a statement by the ministry said

Remdesivir prices may rise after Gilead gets full authorisation from USFDA

In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

National Expert Group meets Covid-19 vaccine makers to discuss road ahead

Representatives from Serum Institute of India, Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals and Biological E met the expert group that is chaired by NITI member Vinod K Paul

France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion

The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said

Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1

The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal

Pharma rally may lose steam as valuations factor in near term gains

Recovery in India business, traction in new launches in the US market are needed to sustain gains

Mankind Pharma partners with South Korea's Daewoong for Covid drug

Will conduct clincial trials on anti-parasitic drug they claim is more effective than remdesivir

Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales

The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing

Alkem Labs Q1 profit jumps 2-fold to Rs 423.2 cr, revenue up at Rs 2,004 cr

Consolidated revenue from operations of the company stood at Rs 2,003.49 crore for the quarter under consideration. It was Rs 1,849.50 crore for the same period a year ago, it added

CVS raises profit forecast, in talks with US to administer Covid vaccines

CVS also said it was working with laboratories to cut down the turnaround time for coronavirus test results, which had spiked in July due to a massive increase in demand for tests

Teva Pharmaceutical's Q2 profit tops forecast, reaffirms 2020 outlook

The company also released with Regeneron Pharmaceuticals results for advanced trials for pain medication fasinumab

Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir

Zenara Pharma announced that it has received approval from the DCGI to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of Covid-19.